rVSV-ZEBOV
Vaccineexperimental
Clinical trial activity
2 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jan 31, 2024 (NCT06100913)
Timeline
Indications
Mechanism of action
- MarburgvirusImmunity, active
Marburgvirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05959421 | Phase 3 | Feb 29, 2024 | Bernhard Nocht Institute for Tropical Medicine, German Federal Ministry of Education and Research, J. W. Goethe University, Monipol Deutschland GmbH, University of Hamburg |
| NCT06100913 | Phase 2 | Jan 31, 2024 | Emory University, Merck, Washington University in St. Louis |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bernhard Nocht Institute for Tropical Medicine | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| German Federal Ministry of Education and Research | Government | 1 | 0 | 1 | 2024 |
| J. W. Goethe University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Merck | For profit | 1 | 0 | 1 | 2024 |
| Monipol Deutschland GmbH | For profit | 1 | 0 | 1 | 2024 |
| University of Hamburg | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Washington University in St. Louis | Academic/Hospital | 1 | 0 | 1 | 2024 |
8 organizations
Page 1 / 1